MedPath

Investigation the effect of Falcaria vulgaris on vitiligo

Phase 3
Conditions
vitiligo.
Vitiligo
Registration Number
IRCT20160627028664N3
Lead Sponsor
Hamedan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
62
Inclusion Criteria

Clinical diagnosis of vitiligo recently or in case of previous diagnosis of non-drug use from one month ago
Normal blood, liver, kidney, anti-nuclear antibody (ANA) tests and eye examination

Exclusion Criteria

Use of effective concomitant treatment in vitiligo
Pregnancy
Personal or family history of light-sensitive
Suffering from light-sensitive diseases such as lupus and porphyria
Use of light-sensitizing drugs such as retinoids and cotrimoxazole

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Size of skin lesions. Timepoint: At the beginning of the study, after 20 days, after a month, after two months. Method of measurement: Based on standard grading VASI and VIDA.;Color of skin lesions. Timepoint: At the beginning of the study, after 20 days, after a month, after two months. Method of measurement: Based on standard grading VASI and VIDA.;Follicular pigmentation. Timepoint: At the beginning of the study, after 20 days, after a month, after two months. Method of measurement: Based on standard grading VASI and VIDA.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath